thalidomide has been researched along with Carcinoma, Non-Small Cell Lung in 30 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To observe the effect of thalidomide in preventing nausea and vomiting induced by emetogenic cisplatin (CDDP) chemotherapy in patients with advanced non-small cell lung cancer." | 9.14 | [The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer]. ( Ha, MW; Li, JP; Liu, XM; Wu, Q; Xing, YD; Yu, YL; Zhu, ZT, 2009) |
| "The addition of thalidomide to pyrotinib is expected to increase the clinical benefit in advanced NSCLC patients with HER2 exon 20 insertions, and reduce the incidence of pyrotinib-related diarrhea." | 5.41 | Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial. ( Ai, X; Chen, Z; Jian, H; Li, Z; Lu, S; Song, Z; Yu, Y; Zhou, Z, 2021) |
| "To observe the effect of thalidomide in preventing nausea and vomiting induced by emetogenic cisplatin (CDDP) chemotherapy in patients with advanced non-small cell lung cancer." | 5.14 | [The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer]. ( Ha, MW; Li, JP; Liu, XM; Wu, Q; Xing, YD; Yu, YL; Zhu, ZT, 2009) |
| "Patients were randomly assigned to the control arm (PC) involving two cycles of induction paclitaxel 225 mg/m(2) and carboplatin area under the curve (AUC) 6 followed by 60 Gy thoracic radiation administered concurrently with weekly paclitaxel 45 mg/m(2) and carboplatin AUC 2, or to the experimental arm (TPC), receiving the same treatment in combination with thalidomide at a starting dose of 200 mg daily." | 2.77 | Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ( Belinsky, SA; Dahlberg, SE; Fitzgerald, TJ; Hoang, T; Johnson, DH; Mehta, MP; Schiller, JH, 2012) |
| "NP regimen combined with thalidomide can significantly prolong the median time to tumor progression in patients with advanced NSCLC." | 2.74 | [Randomized study of thalidomide combined with vinorelbine and cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer]. ( Gu, AQ; Han, BH; Qi, DJ; Shen, J; Song, YY; Xin, Y; Xiong, LW; Zhang, XY, 2009) |
| " We hypothesized that thalidomide, an oral antiangiogenic agent, when combined with chemotherapy, and as maintenance treatment, would improve survival in patients with advanced non-small-cell lung cancer (NSCLC)." | 2.74 | Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. ( Gilligan, D; Gower, N; Hackshaw, A; Jitlal, M; Lee, SM; Ottensmeier, C; Price, A; Rudd, R; Spiro, S; Woll, PJ, 2009) |
| "Thalidomide was given orally every evening starting on day 1 until progressive disease; the starting dose was 200 mg per day, which was escalated by 100 mg per week if tolerated (maximum 1000 mg per day)." | 2.72 | Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer. ( Atkins, JN; Bearden, JD; Case, D; Giguere, JK; Miller, AA, 2006) |
| "Lung cancer is the leading cause of cancer-related mortality in the United States." | 2.45 | Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. ( Horn, L; Sandler, AB, 2009) |
| "Lung cancer is a major public health problem and the leading cause of cancer-related death worldwide." | 2.41 | Angiogenesis inhibitors in lung cancer. ( Herbst, RS; Kim, ES, 2002) |
| "Thalidomide is a widely used anti-angiogenic and immunomodulatory drug with anticancer effects." | 1.51 | Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC. ( Guo, Z; Huang, C; Huang, H; Jiang, L; Liao, Y; Liu, J; Liu, Y; Wang, X; Xia, X; Zhang, F, 2019) |
| "Fourteen patients with advanced lung cancer were scheduled to receive chemotherapy combined with thalidomide." | 1.43 | Thalidomide Combined with Chemotherapy in Treating Patients with Advanced lung Cancer. ( Huang, XE; Li, L, 2016) |
| "Thalidomide has potent anti-inflammatory and anti-angiogenic properties." | 1.38 | Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. ( Brown, NJ; Jitlal, M; Lee, SM; Tin, AW; Woll, PJ; Young, RJ, 2012) |
| "Chemotherapy for the treatment of brain metastases arising from non-small cell lung cancer (NSCLC) has been limited by poor efficacy and high toxicity." | 1.33 | [A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer]. ( Hada, M; Horiuchi, T, 2005) |
| "Thalidomide was begun at 50 mg, p." | 1.33 | Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. ( Anscher, MS; Clough, R; Crawford, J; Dewhirst, MW; Dunphy, F; Garst, J; Herndon, JE; Larrier, N; Marino, C; Marks, LB; Shafman, TD; Vujaskovic, Z; Zhou, S, 2006) |
| "Thalidomide is an anti-angiogenic drug that has shown promise in multiple hematological diseases, and myeloma and other cancers." | 1.32 | The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway. ( Andreola, F; De Luca, LM; DeCicco, KL; Tanaka, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (50.00) | 29.6817 |
| 2010's | 11 (36.67) | 24.3611 |
| 2020's | 4 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, Y | 1 |
| Wang, WC | 1 |
| Shen, WH | 1 |
| Xu, K | 1 |
| Hu, YY | 1 |
| Han, GH | 1 |
| Liu, YB | 1 |
| Ai, X | 1 |
| Song, Z | 1 |
| Jian, H | 1 |
| Zhou, Z | 1 |
| Chen, Z | 1 |
| Yu, Y | 1 |
| Li, Z | 1 |
| Lu, S | 1 |
| Gong, K | 1 |
| Guo, G | 1 |
| Beckley, NA | 1 |
| Yang, X | 1 |
| Zhang, Y | 2 |
| Gerber, DE | 1 |
| Minna, JD | 1 |
| Burma, S | 1 |
| Zhao, D | 1 |
| Akbay, EA | 1 |
| Habib, AA | 1 |
| Donarska, B | 1 |
| Sławińska-Brych, A | 1 |
| Mizerska-Kowalska, M | 1 |
| Zdzisińska, B | 1 |
| Płaziński, W | 1 |
| Łączkowski, KZ | 1 |
| Wang, GH | 1 |
| Wu, PF | 1 |
| Zhang, LH | 1 |
| Fang, P | 1 |
| Chen, Y | 1 |
| Zuo, G | 1 |
| Wu, YQ | 1 |
| Wang, SH | 1 |
| Sun, GP | 1 |
| Sun, X | 1 |
| Xu, Y | 1 |
| Wang, Y | 1 |
| Chen, Q | 1 |
| Liu, L | 1 |
| Bao, Y | 1 |
| Fattore, D | 1 |
| Annunziata, MC | 1 |
| Panariello, L | 1 |
| Marasca, C | 1 |
| Fabbrocini, G | 1 |
| Xia, X | 1 |
| Liu, Y | 1 |
| Liao, Y | 1 |
| Guo, Z | 1 |
| Huang, C | 1 |
| Zhang, F | 1 |
| Jiang, L | 1 |
| Wang, X | 1 |
| Liu, J | 1 |
| Huang, H | 1 |
| Lee, SM | 4 |
| Hackshaw, A | 2 |
| Lowney, AC | 1 |
| McAleer, MA | 1 |
| Kelly, S | 1 |
| McQuillan, RJ | 1 |
| Li, L | 1 |
| Huang, XE | 1 |
| Horn, L | 1 |
| Sandler, AB | 1 |
| Gu, AQ | 1 |
| Han, BH | 1 |
| Zhang, XY | 1 |
| Shen, J | 1 |
| Qi, DJ | 1 |
| Xiong, LW | 1 |
| Xin, Y | 1 |
| Song, YY | 1 |
| Dudek, AZ | 1 |
| Lesniewski-Kmak, K | 1 |
| Larson, T | 1 |
| Dragnev, K | 1 |
| Isaksson, R | 1 |
| Gupta, V | 1 |
| Maddaus, MA | 1 |
| Kratzke, RA | 1 |
| Rudd, R | 1 |
| Woll, PJ | 2 |
| Ottensmeier, C | 1 |
| Gilligan, D | 1 |
| Price, A | 1 |
| Spiro, S | 1 |
| Gower, N | 1 |
| Jitlal, M | 2 |
| Jazieh, AR | 1 |
| Komrokji, R | 1 |
| Gupta, A | 1 |
| Patil, S | 1 |
| Flora, D | 1 |
| Knapp, M | 1 |
| Issa, M | 1 |
| Abdel Karim, N | 1 |
| Yu, YL | 1 |
| Zhu, ZT | 1 |
| Li, JP | 1 |
| Ha, MW | 1 |
| Liu, XM | 1 |
| Wu, Q | 1 |
| Xing, YD | 1 |
| Zhang, H | 2 |
| Chen, J | 1 |
| Zhao, H | 1 |
| Zeng, X | 1 |
| Qing, C | 1 |
| Hoang, T | 1 |
| Dahlberg, SE | 1 |
| Schiller, JH | 1 |
| Mehta, MP | 1 |
| Fitzgerald, TJ | 1 |
| Belinsky, SA | 1 |
| Johnson, DH | 1 |
| Decker, RH | 1 |
| Lynch, TJ | 1 |
| Young, RJ | 1 |
| Tin, AW | 1 |
| Brown, NJ | 1 |
| Goldman, B | 1 |
| DeCicco, KL | 1 |
| Tanaka, T | 1 |
| Andreola, F | 1 |
| De Luca, LM | 1 |
| Hada, M | 1 |
| Horiuchi, T | 1 |
| Anscher, MS | 1 |
| Garst, J | 1 |
| Marks, LB | 1 |
| Larrier, N | 1 |
| Dunphy, F | 1 |
| Herndon, JE | 1 |
| Clough, R | 1 |
| Marino, C | 1 |
| Vujaskovic, Z | 1 |
| Zhou, S | 1 |
| Dewhirst, MW | 1 |
| Shafman, TD | 1 |
| Crawford, J | 1 |
| Dowlati, A | 1 |
| Subbiah, S | 1 |
| Cooney, M | 1 |
| Rutherford, K | 1 |
| Mekhail, T | 1 |
| Fu, P | 1 |
| Chapman, R | 1 |
| Ness, A | 1 |
| Cortas, T | 1 |
| Saltzman, J | 1 |
| Levitan, N | 1 |
| Warren, G | 1 |
| Miller, AA | 1 |
| Case, D | 1 |
| Atkins, JN | 1 |
| Giguere, JK | 1 |
| Bearden, JD | 1 |
| Pérol, M | 1 |
| Arpin, D | 1 |
| Brock, CS | 1 |
| Kim, ES | 1 |
| Herbst, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Pyrotinib Combined With Thalidomide in Advanced Non-Small-Cell Lung Cancer With HER2 Exon 20 Insertions: A Prospective, Single-arm, Open-label Phase II Study[NCT04382300] | Phase 2 | 39 participants (Anticipated) | Interventional | 2020-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for thalidomide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2009 |
[Angiogenesis and lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bio | 2007 |
Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Smal | 2002 |
Angiogenesis inhibitors in lung cancer.
Topics: Angiogenesis Inhibitors; Angiostatins; Carcinoma, Non-Small-Cell Lung; Collagen; Cyclohexanes; Endos | 2002 |
10 trials available for thalidomide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Topics: Acrylamides; Aminoquinolines; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocol | 2021 |
A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Fre | 2013 |
[Randomized study of thalidomide combined with vinorelbine and cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2009 |
Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcino | 2009 |
Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2009 |
Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell | 2009 |
[The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2009 |
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ca | 2012 |
Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Re | 2007 |
Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Smal | 2006 |
16 other studies available for thalidomide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
Topics: Angiogenesis Inhibitors; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Guanine Nucleotide Exchange | 2021 |
Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cytokines; Disease Models, Animal; Drug Resista | 2021 |
Thalidomide derivatives as nanomolar human neutrophil elastase inhibitors: Rational design, synthesis, antiproliferative activity and mechanism of action.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Sc | 2023 |
Use of erlotinib and thalidomide in advanced NSCLC patients with acquired resistance to erlotinib: A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2018 |
Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Mo | 2018 |
Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Immunological; Carcinoma, Non- | 2019 |
Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Line, T | 2019 |
Thalidomide therapy for pruritus in the palliative setting--a distinct subset of patients in whom the benefit may outweigh the risk.
Topics: Aged; Antipruritics; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Female; Humans; Immunosuppressiv | 2014 |
Thalidomide Combined with Chemotherapy in Treating Patients with Advanced lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; | 2016 |
Antitumor and antiangiogenic effects of GA-13315, a gibberellin derivative.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, | 2012 |
Unmet challenges in the use of novel agents in locally advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung | 2012 |
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carbopla | 2012 |
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; A | 2003 |
The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Non-Small-Cell Lung; Cell Division; Female; Humans; Lun | 2004 |
[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lu | 2005 |
Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Female; Fibroblast | 2006 |